SCM Pharma

SCM Pharma is a contract development & manufacturing organisation (CDMO) that develops and makes novel, difficult and dangerous drugs on behalf of our clients. Our formulation development, cGMP manufacturing and aseptic processing services include the sterile filling of liquids, gels and powders (including flammable products) into a range of final dosage forms including ampoules, vials, cartridges, syringes and bottles. So if you’re a pharmaceutical, biotech, medical device or healthcare institution in need of formulation development, clinical manufacturing or contract filling involving a complex product or process – let’s talk.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

No items found

.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.wpv-pagination-nav-links[data-toolset-views-view-pagination-block="33746bd812994fc2d16011719be6c6d7"] { text-align: left;justify-content: flex-start; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] { text-align: center; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__link { background-color: rgba( 6, 147, 227, 1 );font-size: 16px;font-weight: bold; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__link:hover { background-color: rgba( 142, 209, 252, 1 );border-radius: 5px; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__icon { font-family: dashicons;margin-left: 8px; } .tb-button[data-toolset-blocks-button="4a331536cc9a2c84f1f1e0c68c5bad79"] .tb-button__icon::before { content: '\f465'; }   .tb-field[data-toolset-blocks-field="2352d76bb895ac4d7e6623b3996ba2ab"] { font-weight: bold; }  .tb-fields-and-text[data-toolset-blocks-fields-and-text="be25192e3b17b888e76f432f0e43e989"] { background-color: rgba( 142, 209, 252, 1 );padding-top: 5px;padding-bottom: 5px; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="03586fe69ea5b5174ebf265d564b8feb"] { padding: 0px 0px 5px 0px;margin-bottom: 10px;border-bottom: 2px solid rgba( 204, 203, 203, 1 ); } h3.tb-heading[data-toolset-blocks-heading="993a682c67afb3c5e9ef718484910c20"]  { font-size: 16px;color: rgba( 0, 51, 153, 1 );padding-bottom: 5px; }  @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .tb-container .tb-container-inner{width:100%;margin:0 auto}  } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}   .tb-container .tb-container-inner{width:100%;margin:0 auto}  } 

Company Details

SCM Pharma

Unit 6 Regents Drive, Low Prudhoe Industrial Estate, Prudhoe, Northumberland, NE42 6PX, United Kingdom

+44(0) 1661 833 693

Website

How I’m helping to #BreakTheBias: International Women’s Day

Press Releases | March 8, 2022 | Lucid Group Communications Limited

What do you think of when you imagine a scientist? Who do you see in a lab coat? Gender stereotypes and assumptions are rife and, as a child, the thought...

How do doctors want to engage with pharma on new products?

White Papers and Resources | March 8, 2022 | M3 (EU)

More than 80% of European doctors agree they are interested in staying up-to-date with new developments about pharmaceutical products. But what influences their choice of treatment and how do they...

Virtual collaboration tools to reduce “digital overload”

White Papers and Resources | March 7, 2022 | Impetus Digital

Considering its impact on our health and productivity, digital overload is clearly something that we need to take seriously.

Extraordinary lives: advancing change in rare diseases

Press Releases | March 4, 2022 | Lucid Group Communications Limited

Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. On this day across the globe, the rare...

Extraordinary lives: advancing change in rare diseases

Videos and Podcasts | March 4, 2022 | Lucid Group Communications Limited

We are extending the conversation for Rare Disease Day by continuing to raise awareness and generate change for the 300 million people worldwide living with a rare disease, their families...

Stand-out Marketing: How to Stay One Step Ahead in Pharma

White Papers and Resources | March 4, 2022 | Dice Medical Communications

What do you need to do in order to stand out from the crowd in Pharma marketing? (Article written February 26th 2022)

Improving healthcare for rare disease patients

White Papers and Resources | March 4, 2022 | IGNIFI

Following on from Rare Disease Day 2022, we decided to take a deeper look into the patient journey of those living with a rare health condition. In this blog, we...

Gamifying Remote Patient Monitoring

Videos and Podcasts | March 3, 2022 | Impetus Digital

Dr. Emilia Molimpakis, CEO & Co-founder of Thymia, shares how their platform uses video games based on neuropsychology, alongside analyses of facial microexpressions and speech, to quickly, accurately, and objectively...

Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)

Press Releases | March 3, 2022 | Avalere Health

Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed...

Onyx Health Announces a “Double Hatrick” of New Appointments

Press Releases | March 3, 2022 | Onyx Health

Onyx Health continues to expand with six new appointments to its creative and communication teams, due to increased growth in its international client portfolio work.